The conjugation of benzoyl-CoA with the aliphatic and acidic amino acids by glycine N-acyltransferase, as well as the amides of the latter group, was investigated. Bovine and human liver benzoyl-amino acid conjugation were investigated using electrospray ionization tandem mass spectrometry (ESI-MS-MS). Bovine glycine N-acyltransferase catalyzed conjugation of benzoyl-CoA with Gly (Km(Gly) = 6.2 mM), Asn (Km(Asn) = 129 mM), Gln (Km(Gln) = 353 mM), Ala (Km(Ala) = 1573 mM), Glu (Km(Glu) = 1148 mM) as well as Ser in a sequential mechanism. In the case of the human form, conjugation with Gly (Km(Gly) = 6.4 mM), Ala (Km(Ala) = 997 mM), and Glu was detected. The presence of these alternative conjugates did not inhibit bovine glycine N-acyltransferase activity significantly. Considering the relatively low levels at which these conjugates are formed, it is unlikely that they will have a significant contribution to acyl-amino acid conjugation under normal conditions in vivo. However, their cumulative contribution to acyl-amino acid conjugation under metabolic disease states may prove to have a useful contribution to detoxification of elevated acyl-CoAs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/(sici)1099-0461(2000)14:2<102::aid-jbt6>3.0.co;2-h | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma.
J Cell Mol Med
November 2024
Department of Interventional Angiology, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Glycine N-acyltransferase (GLYAT), known to influence glycine metabolism, has been implicated in the progression of various malignant tumours. However, its clinical relevance in hepatocellular carcinoma (HCC) remains unexplored. Here, GLYAT expression levels in HCC tissues were significantly reduced compared to normal liver tissues.
View Article and Find Full Text PDFGLYAT suppresses liver cancer and clear cell renal cell carcinoma progression by downregulating ROCK1 expression.
Transl Cancer Res
September 2024
Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: The liver and kidney are important metabolic organs in the body and common sites of tumor occurrence. Glycine-N-acyltransferase (GLYAT) is primarily expressed in the liver and kidney and downregulated in several tumors. But its specific functions and molecular mechanisms in liver cancer and clear cell renal cell carcinoma (ccRCC) have not yet been fully elucidated.
View Article and Find Full Text PDFPharmacokinetics of aspirin: evaluating shortcomings in the literature.
Expert Opin Drug Metab Toxicol
August 2024
Focus Area for Human Metabolomics, North-West University, Potchefstroom, South Africa.
Article Synopsis
- - Aspirin is effective for preventing strokes and relieving pain, but its toxicity in some individuals is not well understood, particularly regarding the role of glycine conjugation in its detoxification process.
- - A review of existing literature highlighted the pharmacokinetics of aspirin and the factors influencing its metabolism, noting a lack of clarity around individual enzyme contributions and interindividual variation.
- - The review points out the need for more research on the substrate preferences of the enzyme responsible for aspirin activation and emphasizes that impaired glycine conjugation may contribute to serious health issues like Reye's syndrome and cancer.
Downregulation of Glycine N-Acyltransferase in Kidney Renal Clear Cell Carcinoma: A Bioinformatic-Based Screening.
Diagnostics (Basel)
November 2023
Instituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile.
Clear cell renal cell carcinoma (KIRC) is the most common subtype of renal cell carcinoma (RCC). This form of cancer is characterized by resistance to traditional therapies and an increased likelihood of metastasis. A major factor contributing to the pathogenesis of KIRC is the alteration of metabolic pathways.
View Article and Find Full Text PDFDecreased Expression of GLYATL1 Predicts Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Int J Gen Med
August 2023
Department of Urology, Meizhou Academy of Medical Sciences, Meizhou People's Hospital, Meizhou, Guangdong Province, People's Republic of China.
Background: GLYATL1 is a member of the glycine-N-acyltransferase family, which catalyses acyl group transfer. The role of GLYATL1 in cancer is largely unknown; therefore, the potential value of GLYATL1 in clear cell renal cell carcinoma (ccRCC) was explored.
Methods: The ccRCC gene expression profiles and clinical data were obtained from the University of California Santa Cruz Xena platform.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!